ECCO 2018: Returning to a normal life with IBD
Even with access to more potent and sophisticated drugs than ever before, IBD professionals still have a long way to go in optimising treatment and alleviating the long-term… read more.
Even with access to more potent and sophisticated drugs than ever before, IBD professionals still have a long way to go in optimising treatment and alleviating the long-term… read more.
Perianal fistula is a debilitating complication in CD which affects up to 50% of patients in the course of their disease…
Professor Paul G. Richardson MD (R.J. Corman Professor, Medicine, Harvard Medical School, Boston, USA) and Dr Karthik Ramasamy (Oxford Oncology and Haematology Centre) discuss important learnings from real-world… read more.
There were lots of updates from various studies in myeloma at ASH 2017. Above, Professor Sagar Lonial (Emory University School of Medicine, Atlanta, GA) discusses data presented showing… read more.
The chair of the UK Myeloma Research Alliance, Professor Gordon Cook (Leeds Teaching Hospitals Trust) highlights some of the data presented from the UK, including data from the… read more.
As usual, there was a lot of new data in at ASH 2017 in myeloma. Above Professor S Vincent Rajkumar (Mayo Clinic, Rochester, USA) gives a great overview of… read more.
The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.
Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.
Professor Stephen Ansell (Mayo Clinic, USA) discusses who might benefit most from A+AVD upfront in HL. Interview by Esther Drain.
Professor Anas Younes (MSKCC, New York), Professor John Radford (Manchester) and Dr Graham Collins (Oxford). Interviews by Esther Drain. Once again ASH provided much food for thought and above leading experts discuss their… read more.
Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.
Article written by Tom Collins. Interviews by Esther Drain. Replacing bleomycin with brentuximab vedotin (A+AVD) in the traditional regimen for previously untreated Hodgkin lymphoma patients significantly improved modified… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.